1. Home
  2. JWEL vs CVKD Comparison

JWEL vs CVKD Comparison

Compare JWEL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jowell Global Ltd.

JWEL

Jowell Global Ltd.

N/A

Current Price

$2.24

Market Cap

5.7M

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$1.09

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JWEL
CVKD
Founded
2012
2022
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.2M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
JWEL
CVKD
Price
$2.24
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
71.7K
1.1M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$1.14
52 Week High
$5.17
$14.64

Technical Indicators

Market Signals
Indicator
JWEL
CVKD
Relative Strength Index (RSI) 45.18 25.12
Support Level $2.11 N/A
Resistance Level $2.54 $2.23
Average True Range (ATR) 0.28 0.17
MACD -0.07 -0.01
Stochastic Oscillator 16.94 2.61

Price Performance

Historical Comparison
JWEL
CVKD

About JWEL Jowell Global Ltd.

Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: